The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir
There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase
Ahead of a planned filing in the US in the coming months, Teva feels that there is “real excitement” about the firm’s TV-44749 proposed long-acting injectable olanzapine product, as Teva’s first LAI
Ahead of the impending erosion of its core US generic Revlimid (lenalidomide) beginning next year, Teva has announced plans to axe around 8% of its global workforce as part of a newly-unveiled initiat